EUCTR2013-000798-59-HU进行中（未招募）1 期
Phase III, open-label, multi-centre study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed endometriosis - Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed endometriosis
ovalon S.A0 个研究点目标入组 142 人开始时间: 2016年5月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Premenopausal women aged between 18 and 45 years inclusive;
- •2.Clinical diagnosis of endometriosis within the last 5 years and indicated for hormonal suppression therapy. Clinical diagnosis should be based on clinical symptoms of endometriosis (such as chronic pelvic pain, dyspareunia, cyclic intestinal pain [bloating/diarrhoea/constipation], uterine cramping in young females, severe dysmenorrhea, dyspareunia, ovulation pain, cyclical/menstrual symptoms with or without abnormal bleeding, infertility, chronic fatigue) confirmed by laparoscopy with or without histology and/or transvaginal/rectal ultrasound (bladder, ovarian or rectum locations) and/or enema studies (for deeply infiltrating endometriosis);
- •3.Good physical and mental health as judged by the investigator determined by medical history, physical examination, clinical laboratory and vital signs;
- •4.Willing to provide informed consent in writing;
- •5.Willing to use non-hormonal anti-conception method (male/female condom/copper intrauterine device [IUD]) from Screening (Visit 1; Day -28 to Day -4) till the end of treatment period (Visit 14; Day 85±2 days);
- •6.Willing and able to attend the scheduled study visits and to comply with the study procedures;
- •7.Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 142
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous or current hormonal treatment for endometriosis, including GnRH receptor agonists, GnRH receptor antagonists, within 6 months prior to the screening visit;
- •2.Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) or aspartate transaminase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =2 x upper limit of normal (ULN);
- •3.Moderate (stage 3B) or severe (stage 4 and 5) chronic kidney disease with an estimated glomerular filtration rate (eGFR), using the modification of diet in renal disease (MDRD) equation, <45 mL/min/1,73 m2;
- •4.Use of contraceptive treatments that interfere with oestradiol plasma level 1 week (or 5 half lives; whichever is longest) before IMP administration;
- •5.Has endometriosis surgery scheduled for between the Screening and Enrolment visit. (Endometriosis surgery allowed following Visit 14 [Day 85±2 days]);
- •6.Implanted progestin treatment should be released at least 1 month before study enrolment;
- •7.Has received an investigational drug within the last 28 days before the Screening visit (Visit 1) or longer if considered to possibly influencing the outcome of this study;
- •8.Has an unstable medical condition or chronic disease such as but not limited to neurological hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease;
- •9.History or presence of any malignancy other than treated squamous cell/basal cell carcinoma of the skin within the last 5 years;
- •10.Evidence (including clinically significant abnormal bilirubin and/or albumin values) or history of chronic hepatic disease;
- •11.Have a repeatable prolongation of the QTc interval at screening (mean QTcB =450 ms); or personal or family history of long QT syndrome or significant risk factors of prolonged QT interval arrhythmias. (as determined by the investigator);
- •12.Patient for which a possible loss in bone mass which in the judgment of the investigator would affect the patient's health;
- •13.History of severe uncontrolled asthma, anaphylactic reactions, or severe urticarial and/or angioedema, and particularly, history of hypersensitivity towards any components of the IMP;
- •14.Other abnormal laboratory results which in the judgment of the investigator would affect the patient's health or the outcome of the study;
- •15.Pregnancy (or willingness to become pregnant during the study) or breast-feeding during study period;
- •16.Has an intellectual incapacity or inability to comprehend, precluding adequate understanding or co-operation.
研究者
相似试验
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.Prostate cancerEUCTR2013-000799-14-BEovalon S. A.142
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.Prostate cancerEUCTR2019-000593-32-DEovalon S.A.142
已完成
3 期
Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostate cancerprostate adenocarcinoma10038597prostate cancerNL-OMON42816ovalon S.A.12
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.MedDRA version: 18.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2013-000799-14-NLovalon S. A.142
未知
3 期
Phase 3, multicenter, open-label study to evaluate the safety and efficacy of long-term administration of TAK-085 to the patients with hypertriglyceridemiaHypertriglyceridemiaJPRN-jRCT2080220904Takeda Pharmaceutical Company Limited